

CURRICULUM VITAE

Last Name Oh; First Name Yeon-Mok

Citizenship: South Korea

Certification No. of medical doctor: 40852

Title: Professor

Affiliation:

Department of Pulmonary and Critical Care Medicine; Asthma Center; Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine

Asan Medical Center, 88, Olympic-ro, 43-Gil, Songpa-Gu, Seoul 138-736, South Korea

Education & Qualification

GCP Training

- June 27 2022 GCP Training for Investigators
Education of persons conducting clinical trials, etc
- Apr 23 2021 GCP Training for Investigators
Education of persons conducting clinical trials, etc
- Nov 18 2020 GCP Training for Investigators
Education of persons conducting clinical trials, etc
- Apr 21 2020 GCP Training for Investigators
Education of persons conducting clinical trials, etc
- Dec 10 2019 GCP Training for Investigators
Education of persons conducting clinical trials, etc
- Jun 20 2018 GCP Training for Investigators
Education of persons conducting clinical trials, etc
(Korea Centers for Disease Control and Prevention)
- Mar 10 2017 CP Training for Investigators
Education of persons conducting clinical trials, etc
- OCT 27 2016 CP Training for Investigators
Education of persons conducting clinical trials, etc

2002 Certified as a specialist in pulmonary medicine, South Korea

1995 Certified as a specialist in internal medicine, South Korea

2006 Ph.D., Department of Internal Medicine, Seoul National University Medical College, Seoul, South Korea

1994 Master of Science, Department of Internal Medicine, Seoul National University Medical College, Seoul, South Korea

1990 M.D. (summa cum laude), Seoul National University Medical College, Seoul

Graduate Medical Training

June-July, 2006. Visiting Professor, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA

2000-2002 Postdoctoral fellowship, Cardiovascular Research Institute, Univ. California San Francisco, San Francisco, CA

1998-1999 Clinical fellowship, Pulmonary Division, Department of Internal Medicine, Seoul National University Hospital

1991-1995 Residency, Department of Internal Medicine, Seoul National University Hospital

1990-1991 Internship, Seoul National University Hospital

Faculty Appointments

2012-Present Professor, Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

2017-2021 Head, Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

2012.3-2013. Head of Asthma Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

2007-2012 Associate professor, Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

2002-2007 Assistant professor, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

1999-2000 Medical staff, Department of Internal Medicine, Syeojong Hospital, Boocheon, South Korea

1996-1998 Medical staff, Department of Internal Medicine, the Daejeon District Army Hospital, Daejeon, South Korea

Memberships

Member Korean Association of Internal Medicine

Member The Korean Academy of Tuberculosis and Respiratory Diseases

Member The Korean Academy of Asthma, Allergy and Clinical Immunology

Member Korean Obstructive Lung Disease Study Group

Member Korean Asthma Study Group

Member American Thoracic Society

Clinical Trial Experience

- 2017 SIT_Phase2 (PI)

Randomized double blind, placebo controlled trial for the evaluation of the efficacy and safety of danirixin administered twice daily for 24 weeks and for the determination of dose in adult

patients with chronic obstructive pulmonary disease (COPD).

- 2019 SIT Phase3 (PI) A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammation Protocol number: EFC15804

- 2020 SIT Phase 3 (Sub-I) A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensinetrine over 24 Weeks (With a 48-Week Safety Subset) in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease.

- 2020 SIT Phase 3 (Sub-I) A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 52-Week, Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Non-Cystic Fibrosis Bronchiectasis

- 2021 Phase2a (PI) A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

- 2021 SIT Phase 3 (PI) Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations

- 2021 SIT Phase IIa (Sub-I) A Two-part Phase IIa Randomised, Double-blind, Placebo-controlled, Dose-ranging, Multi-centre Study to Assess Efficacy and Safety of Three Inhaled Dose Levels of AZD1402 Administered as a Dry Powder Twice Daily for Four Weeks in Adults with Asthma on Medium Dose Inhaled Corticosteroids

- 2021 A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE)

- 2022 A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (OBERON)

- 2022 A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis (Airleaf™)

Publications

Original Papers

1: Park JS, Cho R, Kang EY, Oh YM. Effect of Slit/Robo signaling on regeneration in lung emphysema. *Exp Mol Med*. 2021 May;53(5):986-992. doi: 10.1038/s12276-021-00633-8. Epub 2021 May 25. PMID: 34035465; PMCID: PMC8178402.

2: Han DW, Lee JS, Oh YM, Lee SD, Kim HJ, Lee SW. The Clinical Course of Asthma After Withdrawal of Inhaled Corticosteroids. *J Allergy Clin Immunol Pract*. 2021 Mar;9(3):1295-1303.e3. doi: 10.1016/j.jaip.2020.09.056. Epub 2020 Oct 10. PMID: 33049393.

3: Cho YH, Seo JB, Lee SM, Kim N, Yun J, Hwang JE, Lee JS, Oh YM, Do Lee S, Loh LC, Ong CK. Radiomics approach for survival prediction in chronic obstructive pulmonary disease. *Eur Radiol*. 2021 Oct;31(10):7316-7324. doi: 10.1007/s00330-021-07747-7. Epub 2021 Apr 13. PMID: 33847809.

4: Kim MA, Park HW, Kim BK, Park SY, Ban GY, Lee JH, An J, Shim JS, Lee Y, Won HK, Lee HY, Sohn KH, Kang SY, Park SY, Lee H, Kim MH, Kwon JW, Yoon SY, Lee JH, Rhee CK, Moon JY, Lee T, Kim SR, Park JS, Kim SH, Jeong JW, Kim SH, Koh YI, Oh YM, Jang AS, Yoo KH, Cho YS; Korean Academy of Asthma, Allergy, and Clinical Immunology (KAACI), the Working Group on Severe Asthma. Specialist Perception of Severe Asthma in Korea: A Questionnaire Survey. *Allergy Asthma Immunol Res*. 2021 May;13(3):507-514. doi: 10.4168/aair.2021.13.3.507. PMID: 33733643; PMCID: PMC7984944.

5: Jeong I, Lim JH, Park JS, Oh YM. Aging-related changes in the gene expression profile of human lungs. *Aging (Albany NY)*. 2020 Nov 9;12(21):21391-21403. doi: 10.18632/aging.103885. Epub 2020 Nov 9. PMID: 33168785; PMCID: PMC7695411.

6: Park YE, Sung H, Oh YM. Respiratory Viruses in Acute Exacerbations of Bronchiectasis. *J Korean Med Sci*. 2021 Aug 30;36(34):e217. doi: 10.3346/jkms.2021.36.e217. PMID: 34463061; PMCID: PMC8405402.

7: Yun J, Cho YH, Lee SM, Hwang J, Lee JS, Oh YM, Lee SD, Loh LC, Ong CK, Seo JB, Kim N. Deep radiomics-based survival prediction in patients with chronic obstructive pulmonary disease. *Sci Rep*. 2021 Jul 26;11(1):15144. doi: 10.1038/s41598-021-94535-4. PMID: 34312450; PMCID: PMC8313653.

8: Choi H, Lee H, Ra SW, Kim HK, Lee JS, Um SJ, Kim SH, Oh YM, Kwon YS, On Behalf Of The Kmbarc. Clinical Characteristics of Patients with Post-Tuberculosis Bronchiectasis: Findings from the KMBARC Registry. *J Clin Med*. 2021

Sep 30;10(19):4542. doi: 10.3390/jcm10194542. PMID: 34640560; PMCID: PMC8509664.

9: Hwang JJ, Shin SH, Kim YJ, Oh YM, Lee SD, Kim YH, Choi CW, Lee JS. Epidemiology of Antiphospholipid Syndrome in Korea: a Nationwide Population-based Study. *J Korean Med Sci.* 2020 Feb 10;35(5):e35. doi: 10.3346/jkms.2020.35.e35. PMID: 32030922; PMCID: PMC7008065.

10: Moon J, Oh YM, Ha SJ. Perspectives on immune checkpoint ligands: expression, regulation, and clinical implications. *BMB Rep.* 2021 Aug;54(8):403-412. doi: 10.5483/BMBRep.2021.54.8.054. PMID: 34078531; PMCID: PMC8411045.guideline. *J Korean Med Sci.* 2014 Aug;29(8):1108-12. doi: 10.3346/jkms.2014.29.8.1108. Epub 2014 Jul 30. PubMed PMID: 25120321; PubMed Central PMCID: PMC4129203.

(Truncated)

238: Oh YM, Kim YS, Yoo SH, Kim SK, Kim DS. Association between stress and asthma symptoms: a population-based study. *Respirology.* 2004 Aug;9(3):363-8. PubMed PMID: 15363009.

Book chapters

Oh YM. Maximum expiratory pressure and maximum inspiratory pressure. In: Kim WD ed. *Pulmonary function test 1st ed.* UUP, Seoul; 2004.

Oh YM. COPD Text Book - Heterogeneity and Personalized Treatment. Sang-Do Lee, Mailan K. Han, Norbert F. Voelkel, Paul Jones, Edwin K. Silverman, Rubin M. Tuder, Joon Beom Seo, Yeon-Mok Oh, Sei Won Lee, Jae Seung Lee, Young Sam Kim, et al. Springer; 2017

Grants

2018-2021 \$390,000 Grants for Elucidation of the lung regeneration mechanism of Slit/Robo system in chronic lung disease funded by Ministry of Science and ICT, Gwacheon, Korea

2016-2021 \$2,735,000 Grants for The development of therapeutics in chronic obstructive pulmonary disease using pioglitazone augmented stem cells funded by Ministry of Health and Welfare, Sejong, Korea

2016-2018 \$260,000 Grants for Effect of Inhaler Therapy for Tuberculous Destroyed Lung - Observational Study funded by National Evidence-based Healthcare Collaborating Agency, Seoul, Korea

2015-2021 \$3,600,000 Grants for Asan-Minnesota Institute for Innovating Transplantation (AMIT) funded by Ministry of Science and ICT, Gwacheon, Korea

2015-2016 \$100,000 Grants for Pulmonary rehabilitation program for COPD patients: cost-effectiveness evaluation and strategies for introduction funded by Korea Centers for Disease Control & Prevention, Cheongju, Korea

2013-2015 \$343,600 Grants for Clinical Research Network for Chronic Obstructive Airway Disease funded by Korea Health Industry Development Institute, Cheongwon, Korea

2010~2011 \$60,000, Grants for the Quality Control of Pulmonary Function Test, the Korean Health and Nutrition Examination Survey, Korean Centers for Disease Control and Prevention, Seoul, Korea

2004~2005 \$40,000, Grants for Teams of Proceeding Researchers, funded by the Asan Institute for Life Sciences, Seoul, Korea

2002~2003 \$15,000, Grants for New Researchers funded by the Asan Institute for Life Sciences, Seoul, Korea